In-vitro and in-vivo erosion profiles of hydroxypropylmethylcellulose (HPMC) matrix tablets.
The purpose of this study was to evaluate and compare the in-vitro and in-vivo erosion profiles of two tablet formulations primarily consisting of hydroxypropylmethylcellulose (HPMC) and lactose. HPMC was used at concentrations below and above the reported values for polymer percolation threshold in controlled release matrix formulations: 20 and 40% (w/w) HPMC. In-vitro erosion behaviour was studied using traditional gravimetric and scintigraphic methods, with radiolabelled charcoal used as a marker to quantify erosion profiles in scintigraphic studies. Six healthy male subjects participated in a randomised crossover scintigraphic erosion study. Both in-vitro and in-vivo erosion profiles determined using the gravimetric and/or scintigraphic method for matrix tablets were dependent upon the concentration of HPMC, and erosion was faster for tablets containing 20% (w/w) HPMC than those containing 40% (w/w) HPMC. Good correlation was found between in-vitro gravimetric and scintigraphic erosion profiles for both tablets. Tablets containing 40% (w/w) HPMC (polymer level above percolation threshold) demonstrated robust in-vivo performance and showed stronger correlation with in-vitro erosion profiles. The study demonstrated that a matrix formulation with a lower concentration of HPMC and higher lactose concentration is more likely to perform poorly in the in-vivo environment.
Ghimire
Manish
M
Strathclyde Institute of Pharmacy and Biomedical Sciences, University of Strathclyde, Glasgow G4 0NR, UK. mghimire@colorcon.co.uk
Hodges
Lee Ann
LA
Band
Janet
J
O'Mahony
Bridget
B
McInnes
Fiona J
FJ
Mullen
Alexander B
AB
Stevens
Howard N E
HN
D000328:Adult; D002606:Charcoal / Q000737:chemistry; D018592:Cross-Over Studies; D003692:Delayed-Action Preparations / Q000008:administration & dosage* / Q000737:chemistry / Q000493:pharmacokinetics; D004337:Drug Carriers / Q000008:administration & dosage / Q000737:chemistry* / Q000493:pharmacokinetics; D004339:Drug Compounding; D006801:Humans; D007785:Lactose / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000737:chemistry / Q000493:pharmacokinetics; D008297:Male; D008747:Methylcellulose / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000737:chemistry / Q000493:pharmacokinetics; D011877:Radionuclide Imaging; D012995:Solubility; D013607:Tablets; D016284:Technetium Tc 99m Pentetate; D014783:Viscosity; D055815:Young Adult
D003692:Delayed-Action Preparations; D004337:Drug Carriers; D013607:Tablets; C509290:hydroxypropylmethylcellulose-lactose matrix; D002606:Charcoal; D008747:Methylcellulose; D007785:Lactose; D016284:Technetium Tc 99m Pentetate